tiprankstipranks
Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR
US Market
MRKR
Marker Therapeutics
RESEARCH TOOLSreports

Marker Therapeutics (MRKR) Stock News & Sentiment

601 Followers
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
Premium
Ratings
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
20d ago
MRKR
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
Premium
Company Announcements
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
21d ago
MRKR
Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
Premium
Ratings
Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
21d ago
MRKR
Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet
1M ago
MRKR
Marker Therapeutics Sets Date for 2026 Annual Meeting
Premium
Company Announcements
Marker Therapeutics Sets Date for 2026 Annual Meeting
2M ago
8K
MRKR
Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target
Premium
Ratings
Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target
3M ago
MRKR
Marker Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Marker Therapeutics Reports Q3 2025 Financial Results
5M ago
MRKR
More MRKR News >

MRKR News on the Web

Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
TipRanks News
Bullish
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
TipRanks News
Bearish
Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
TipRanks News
Bullish
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
Zacks
Neutral
Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)
TipRanks News
Neutral
H.C. Wainwright Sticks to Its Buy Rating for Marker Therapeutics (MRKR)
TipRanks News
Bullish
Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet
TipRanks News
Bullish
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Zacks
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MRKR’s Media Buzz Sentiment?
Currently, no data Available
What is MRKR’s weekly average amount of articles?
Currently, no data Available
What is MRKR’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
NBIXNeurocrine
AORTArtivion
STAAStaar Surgical
HUMHumana
ORGOOrganogenesis Holdings
Showing the stocks with the most bullish news sentiment over the past week